Investors Count

12

Funding, Valuation & Revenue

3 Fundings

IceCure Medical's latest funding round was a PIPE for $6M on August 19, 2020.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

8/19/2020

PIPE

$6M

$XXM

0

FY undefined

1

Other Investors

$XXM

0

FY undefined

10

IPO

$XXM

0

FY undefined

10

Date

8/19/2020

Round

PIPE

Other Investors

IPO

Amount

$6M

Investors

Valuation

$XXM

$XXM

$XXM

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

Sources

1

10

10

Start free trial
New call-to-action

IceCure Medical Investors

12 Investors

IceCure Medical has 12 investors. Gal Cohen invested in IceCure Medical's PIPE funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

8/19/2020

8/19/2020

1
PIPE

Angel Investor (Individual)

Israel

8/19/2020

8/19/2020

1
PIPE

Private Equity

United Kingdom

8/19/2020

8/19/2020

1
PIPE

Investment Bank

Israel

00/00/0000

00/00/0000

Yair Capital

Subscribe to see more

Asset/Investment Management

Israel

00/00/0000

00/00/0000

Reut Alfia

Subscribe to see more

Angel Investor (Individual)

Israel

First funding

8/19/2020

8/19/2020

8/19/2020

00/00/0000

00/00/0000

Last Funding

8/19/2020

8/19/2020

8/19/2020

00/00/0000

00/00/0000

Investor

Yair Capital

Reut Alfia

Rounds

1
PIPE
1
PIPE
1
PIPE

Subscribe to see more

Subscribe to see more

Board Seats

Type

Angel Investor (Individual)

Private Equity

Investment Bank

Asset/Investment Management

Angel Investor (Individual)

Location

Israel

United Kingdom

Israel

Israel

Israel

New call-to-action

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.